hous built initi outperform
initi coverag aeri pharmaceut outperform rate
price target recent launch rhopressa first-in-class rho kinas
inhibitor reduc intra-ocular pressur glaucoma ocular hypertens
patient potenti approv rocklatan fixed-dos combin
rhopressa latanoprost well posit revenu growth
next sever year earli rhopressa launch trend make us comfort
commerci infrastructur believ compani could address sever unmet
need rocklatan rhopressa market also like leverag
infrastructur strong balanc sheet potenti upsid early-stag pipelin
focus diseas retina
differenti therapi larg glaucoma market rhopressa rocklatan
shown reduc intraocular pressur iop patient glaucoma
ocular hypertens oht iop reduct well-establish
therapeut area sever market class therapi includ gener
note aeri portfolio offer novel mechan increment efficaci
combin current standard care
attract us commerci opportun rhopressa rocklatan approv
launch therapeut market high degre diseas awar
favor demograph trend well-establish treatment regimen
believ base combin factor aeri product could
experi strong uptak near term estim address us
market potenti
leverag infrastructur aeri us sale market infrastructur
consist sale repres note exist sale forc could
leverag rhopressa rocklatan provid opportun margin
improv time also note potenti manufactur effici
recent capital-expenditure invest
rocklatan key valu driver near-term pdufa march rocklatan
key driver valuat outlook confid product
us approv note potenti delay regulatori decis commerci
launch would affect valuat meaning
favor risk/reward profil excit strong top-lin growth
potenti note estim assum us net price stabil
continu rhopressa growth post rocklatan launch key point content
hand price target attribut minim valu ou opportun
could meaning achiev approv reimburs
inc clinic
stage pharmaceut compani
engag discoveri develop
commerci therapi
treatment patient glaucoma
diseas eye product
includ rhopressa roclatan
analyst certif import disclosur see disclosur
inhibitor reduct intra-ocular pressur patient
glaucoma ocular hypertens potenti
approv rocklatan combin therapi
well posit execut commerci next sever
year earli rhopressa launch trend make us comfort
commerci infrastructur believ compani
could address sever unmet need rocklatan
rhopressa market also like leverag
infrastructur strong balanc sheet potenti upsid
earli stage pipelin focus retina diseas
rhopressa us market share outer year
japanes launch probabl
rocklatan us launch share mid-teen outer year
eu launch probabl
gross margin long-term mid-singl digit low-doubl digit
growth spend low single-digit growth sg
expens compani reach steadi state
net oper loss nol balanc use deduct
taxabl incom tax rate thereaft
rocklatan pdufa
rhokiinsa eu regulatori action
roclatan phase mercuri trial data
potenti rhopressa phase data japanese/japanese-american
subject
strong rhopressa growth rocklatan launch
eu approv reimburs rocklatan
favor commerci partnership term strong launch japan
slow volum growth rhopressa rocklatan
declin net price rhopressa rocklatan
declin rhopressa use rocklatan launch
valuat base discount cash flow analysi model sale lead product candid ten-year period assum
termin valu base tail market product project period use discount rate
believ approxim compani weight averag cost capit base risk-fre rate expect market return
beta per bloomberg assum termin valu growth rate retain revenu termin period
upsid risk includ strong rhopressa growth longer term lower oper expens outsid us ou launch strong
uptak downsid risk includ slow volum growth rhopressa rocklatan price pressur oper ineffici
rhopressa commerci declin rocklatan launch
aeri ophthalm pharmaceut compani develop
commerci therapi patient diseas eye includ open-
angl glaucoma retina diseas recent launch rhopressa
us first-in-class rho kinas inhibitor rhopressa once-daili eye
drop reduct elev intraocular pressur iop patient
open-angl glaucoma ocular hypertens oht also pipelin
early-stag asset develop front back
manag highlight sever catalyst next month
exhibit import view rocklatan pdufa us
mercuri trial data eu us commerci uptak trend
note pleas see initi report
product potenti mileston event ind file fda action launch trial top-line data ind file rhopressa ema action eu phase indic descript market us file japan file inddiabet macular edema dme retin vein occlus rvo anintravitr fullybiodegradableimplantthatreleasesth steroid preclin macular degener diabet macular edema diseas hypertens rocklatanglaucoma rhopressa glaucoma netarsudilophthalmicsolutionforreductionofelevatedintraocularpressureinpatientswithopen-angleglaucoma ocular hypertens inc
differenti therapi larg glaucoma market
aeri glaucoma portfolio includ rhopressa netarsudil rocklatan
netarsudil/latanoprost ophthalm solut use reduc iop patient
open-angl glaucoma oht manag iop larg well-
established-therapeut area sever treatment altern aeri portfolio
present novel mechan action differenti therapi
iop-low drug offer increment iop reduct ad
current standard care also note once-nightli dose
attract featur rel standard care
inhibit novel mechan iop reduct
rho-kinas inhibitor lower iop target degener tissu
trabecular meshwork within eye elev iop limit outflow
aqueou humor transpar fluid nourish cornea len exhibit
physic vision www uaf edu
iop maintain balanc product aqueou humor
ciliari bodi drainag trabecular meshwork
uveoscler pathway exhibit illustr panel normal aqueou
flow pass trabecular meshwork red arrow uveoscler
pathway green arrow open-angl glaucoma patient panel
aqueou outflow impair
american academi ophthalmolog eyenet magazin glaucoma pipelin drug target trabecular
exhibit present comparison trabecular meshwork healthi eye
top eye primari open-angl glaucoma bottom
trabecular meshwork healthi eye smooth endotheli surfac
larg space trabecular beam meshwork eye
primari open angl glaucoma poag show fuse trabecula smaller
space beam inhibitor thought shrink cell
cytoskeleton within trabecular meshwork creat space
cell fluid exit therebi reduc iop
normal trabecular meshwork cylindr uveal trabecular beam distinct gener smooth
endotheli surfac cellular border visibl thin arrow larg intertrabecular space
present melanin granul thick arrow seen cell within space
poag trabecular meshwork flat widen uveal trabecula beneath corneoscler
trabecula space seen fewer space visibl vs healthi eye fuse trabecula
seen thick arrow thin arrow melanin granul debri seen surfac
throw first fda
rhopressa first inhibitor approv fda
reduct iop also anticip approv rocklatan aeri combin
therapi around pdufa date note aeri product
well ahead competitor inhibitor class within us market
acknowledg shortcom cross-trial comparison present
clinic data rhopressa rocklatan rel current standard care
rhopressa offer compar efficaci lower dose exhibit
rocklatan improv efficaci rel latanoprost higher advers event
note data present prescrib medic class
iop reduct mmhg roclatan latanoprost diurnal diurnal diurnal diurnal iop mmhgroclatan vs latanoprost rhopressabrimonidin tartratetimolol maleateazopt pilocarpin hcllatanoprost pharmacolog class rho kinas inhibitoralpha agonistbeta blockercarbon anhydras inhibitorcholinerg agonistsprostaglandin analoghalf life hr hrsna day na minsmean iop reduct mmhg mmhg dosag form mg/ml netarsudil mg/ml brimonidin tartrat mg/ml timolol mg/ml brinzolamid mg/ml mg/ml pilocarpin hcl mcg/ml latanoprost administr daili even three time daili daili morningthre time daili four time dailyonc daili eveningconjunctiv hyperemia ocular hyperemia burn sting sensat headach browacheconjunctiv hyperemia corneal verticillataconjunctiv folliclesblur vision blur vision accommod changeblur vision instil site painocular allerg reactionscataract unusu tast irrit burn sting sensat conjunctiv hemorrhag burn sting conjunctiv inject eya pain itch discontinu rate na na date reaction drugcompanyindicationphaseformulationrhopressaaeri inc glaucomamarket ustopicalrocklatanaeri kasei corporationcerebr vasospasmmarket japaninject compani ltd glaucomamarket tanab pharma glaucoma develop spinal cord injuri apsprost cancer i/iisubcutan intraven infus outperform
rhopressa rocklatan approv launch therapeut market
high degre diseas awar steadili increas patient popul
exhibit well-establish treatment regimen unmet need exhibit
believ base combin factor aeri product
could experi strong uptak near term
american academi ophthalmolog
advers event roclatan latanoprost disord conjunctiv hyperemia hemorrhag disord site condit instil site pain site discomfort open-angl glaucoma popul million inc
american academi ophthalmolog glaucoma research foundat review ophthalmolog
target us market opportun
estim aeri address market could us
rhopressa rocklatan combin assum patient current
prostaglandin therapi could constitut initi target market
expans class therapi could add increment
pharmacolog classproduct benefit advers reaction prostaglandin analog bimatoprost latanoprost travoprost increas outflow intraocular fluid uveoscler pathway once-daili dose ocular blur vision sting burn hyperemia foreign bodi sensat itch herp simplex kerat system headach upper respiratori tract symptom alpha agonist epinephrin dipivefrinapraclonidinebrimonidinedecreas product fluid increas drainag possibl neuroprotect ocular allerg sensit minim mydriasi lid retract conjunctiv vasoconstrict sting burn hyperemia conjunctiv follicl system gastrointestin discomfort tast abnorm headach fatigu oral dryness beta-block carteolollevobunololmetipranololtimololdecreas product intraocular fluid once-daili dose ocular sting burn superfici punctat kerat allerg sensit decreas corneal sensit system system hypotens bradycardia diabet mellitu myasthenia gravi certain medic carbon anhydras inhibitor acetazolamidedichlorphenamidemethazolamidedorzolamid brinzolamid decreas product intraocular fluid ocular sting burn allerg sensit blur vision superfici punctat kerat corneal edema system alter tast cholinerg agonistspilocarpineincreas drainag intraocular fluid ocular sting irrit ciliari spasm miosi pupillari block retin detach system headach pain sweat vomit diarrhea saliv bradycardia arrhythmia dyspnearho kinas inhibitor netarsudil ripasudilincreas drainag intraocular fluid trabecular meshworkconjunctiv hyperemia corneal verticillata instil site pain conjunctiv hemorrhag combin medic timolol-dorzolamidetimolol-brimonidin aggress therapi fewer drop better compliancegreat impact iop fewer copay complementari mechan action reduc exposur preserv reduc washout effectmultipl potenti advers reaction combin class outperform
base prescript data note prostaglandin analog account
estim iop medic bottl dispens us pharmaci
exhibit share pharmacolog class
note deriv estim bottl base volum ml dispens volum per bottl
symphoni health oppenheim co inc estim
market opportun estim within prostaglandin class base
view rhopressa could use adjunct therapi patient
bimatoprost travoprost rocklatan could use second-lin
therapi latanoprost patient requir increment iop control exhibit
alpha agonist blocker blocker alpha agonist blocker carbon anhydras inhibitor anhydras inhibitor anhydras inhibitor alpha agonist agonist analog kinas inhibitor pga non-pga address us market inc
symphoni health oppenheim symphoni health data
estim market opportun non-prostaglandin segment
base assumpt medic use patient
inelig prostaglandin therapi target rhopressa assum
use combin prostaglandin target rocklatan
exhibit present analysi
base symphoni script data
assum patient pga intoler
note rhopresssa experienc rel strong uptak sinc launch
april exhibit acknowledg likelihood rhopressa
cannib rocklatan commerci believ rhopressa could
continu address need patient prescrib prostaglandin
latanoprost well elig non-
respons prostaglandin
aeri us sale market infrastructur rhopressa consist
sale repres exist sale forc could commerci rocklatan
us approv provid signific leverag oper incom
estim yield sg margin declin includ
bottl sg inc
estim valuat primarili reli us market potenti
note plan commerci iop-low therapi eu
japan believ rocklatan rhokinsa could attract eu
japan market respect model revenu eu begin
japan probability-adjust respect
rocklatan could compet current market ganfort
bimatoprost/timolol combin market allergan eu
rhokinsa could compet glanatec anoth inhibitor current
market japan rocklatan need demonstr non-inferior ganfort
mercuri trial obtain reimburs eu market anticip
submiss late ema action rhokiinsa file exhibit
manag conduct phase trial japan anticip phase
trial complet prior approv await result clinic trial
present comparison rhokinsa clinic profil glanatec exhibit
acknowledg shortcom cross-trial comparison also note
rhokinsa data specif japanes popul
rhopressa fda label glanatec pmda label rhopressa fda pharmacology/toxicolog nda review evalu
target price base discount cash flow analysi exhibit
model sale lead product candid ten-year period assum
termin valu base tail market product
project period assumpt underli price target
iop reductionmean iop mmhg mmhg ganfort roclatan hr hr hr hr hr hr reactionsconjunctiv hyperemia growth eyelash burn sting sensat eye pruritu superfici punctat kerat eye dryness visual disturb corneal eros eye irrit blephar epiphora eyelid oedema headach rhiniti conjunctiv hyperemia cornea verticillata conjunctiv hemorrhag corneal disord instil site pain rhokinsaglanatec half life hr hrmean iop reduct mmhgdosag form mg/ml netarsudil mg/ml ripasudil incid conjunctiv hyperaemia hyperemiaconjunctiv hyperemiacorn verticillataconjunctiv congestioninstil site painconjunctiv inflammationconjunctiv hemorrhag blephar eye irritationapprov date reaction inc
rhopressa us market share grow outer year japanes
launch probabl adjust
rocklatan us launch share grow mid-teen
outer year eu launch probabl adjust
rhopressa rocklatan gross margin increas
beyond
mid-singl digit low-doubl digit growth spend low
single-digit growth sg expens compani reach
net oper loss nol balanc deduct annual
taxabl incom use tax rate thereaft
discount cash flow use discount rate
believ approxim compani weight averag cost
capit base risk-fre rate expect market return
beta per bloomberg
termin growth rate revenu retain termin
after-tax work cash flow per share discount rate current valu valu valu cash valu rate growth rate outperform
key driver valuat price target rocklatan pdufa
march exhibit show revenu estim rocklatan
confid product us approv note potenti delay regulatori
decis commerci launch would affect valuat meaning
estim one-year delay us launch els equal could theoret lower
price target per share exhibit
base manag comment assum stabl net price
exhibit estim neg impact price target everi
declin net price beyond exhibit
rhopressa rocklatan differenti first-in-class agent
us note sever therapeut altern manag iop
includ gener competit market dynam may erod net price
assum rhopressa could account revenu time
exhibit model market share grow
increas modestli thereaft exhibit rhopressa account
smaller share revenu note weak commerci uptak could impli
neg pressur price target els equal estim theoret
neg impact price target everi reduct rhopressa
market share outer year exhibit
manag prior experi educ vicent anido jr phdpresid ceo ceo chairman windamer ventur spresid ceo combichem inc presid america region allerganb west virginia univers ph univers missouri kansa cityrichard rubinocfo medco health solutionscfochief account offic ata medco health solut member aib account manhattan colleg thoma mitrovp omero corpor presid vice-president vice-president skin allerganvp busi develop allergan miami univers casey kopczynski phdmanag director biotech initi llcchief scientif offic vice-president research ercol biotechco-found director inc ph indiana univers quarterli revenu roclatan rhopressa/roclatan revenu chang us roclatan nananananananananana rhopressa/roclatan nanananananananananatot revenu revenu us roclatan rhopressa/roclatan revenu outperform
annual revenu roclatan rhopressa/roclatan revenu chang us roclatan rhopressa/roclatan revenu revenu us roclatan rhopressa/roclatan revenu quarterli earn incom expens incom tax incom ep changetot inc
adjust annual earn incom expens incom tax incom ep changetot outperform
sheet cash invest expens current asset current asset asset payabl payabl expens current liabil current liabil note non-curr liabil liabil stockhold equiti liabil stockhold equiti inc
stock price compani mention report
